Institute for Diagnostic and Interventional Radiology, University Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany.
Pancreas. 2011 Nov;40(8):1271-5. doi: 10.1097/MPA.0b013e318220e5b9.
To evaluate the effect of chemoembolization on pancreatic cancer liver metastases.
Thirty-two patients with pancreatic cancer liver metastases retrospectively underwent chemoembolization (4- to 8-week intervals). Size-based evaluation (response evaluation criteria in solid tumors [RECIST]) and survival indexes were assessed overall and for sex and number of lesions.
Of the patients, 71.87% showed stable disease, 9.37% partial response (PR) and 18.75% progressive disease (PD). Survival rate for 1, 3, and 5 years from first TACE was 60%, 25%, and 11%, respectively. Median survival time was 16 months and for stable disease group was 20 months. Progression-free survival for 6 months and 1, 3, and 5 years was 84%, 57.3%, 20%, and 10%, respectively. There was significant difference between men and women in response. Survival rates for 1 and 5 years for the men were 80% and 14% and for the women were 47% and 0%. There was no significant difference between oligonodular liver lesion (n < 5) and multinodular (n > 5) groups. Survival rates for 1 and 5 years for oligonodular were 84% and 14%, and for multinodular was 50% and 0%.
Repetitive TACE resulted in a relevant response for the control of liver metastases of pancreatic cancer with respectable median survival time. Interestingly, the number of lesions, statistically, was not an effective factor.
评估化疗栓塞治疗胰腺癌肝转移的效果。
回顾性分析 32 例胰腺癌肝转移患者，间隔 4-8 周行化疗栓塞治疗。评估总生存及生存情况（实体瘤疗效评价标准 [RECIST]）和性别、病灶数量。
患者疾病稳定占 71.87%，部分缓解（PR）占 9.37%，进展（PD）占 18.75%。从首次 TACE 开始的 1、3、5 年生存率分别为 60%、25%、11%。中位生存时间为 16 个月，疾病稳定组为 20 个月。无进展生存 6 个月、1、3、5 年分别为 84%、57.3%、20%、10%。性别间疗效存在显著差异。男性 1 年和 5 年生存率为 80%和 14%，女性为 47%和 0%。寡结节肝转移（n < 5）和多结节（n > 5）之间生存无显著差异。寡结节 1 年和 5 年生存率为 84%和 14%，多结节为 50%和 0%。
重复 TACE 对控制胰腺癌肝转移有一定疗效，中位生存时间尚可。有趣的是，病灶数量在统计学上不是一个有效因素。
